Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1Adenoviridae Infections 1

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interferon-beta × Sarcoma × Clear all
NCT00031083 2020-11-17

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

Biogen

Phase 1 Completed
12 enrolled
CNSSarcoma

Adenoviridae Infections, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡